Rexahn Pharmaceuticals, Inc. (AMEX:RNN) gained 25.26% up to $1.19 on no news; but has been garnering attention from investment researchers this week. RNN stock has gained more than 70% since Monday on heavy volume.  Based in Rockville, Maryland, Rexahn Pharmaceuticals, Inc., is a clinical stage biopharmaceutical company which discovers, develops, and commercializes treatments for cancer, central nervous system disorders, sexual dysfunction in the US. The company currently has three drug candidates in Phase II clinical trials which include Serdaxin for the treatment of depression, Archexin for the treatment of renal cell carcinoma and pancreatic cancer; and Zoraxel for the treatment of sexual dysfunction.

GeoPharma, Inc. (NASDAQ:GORX) gained 11.11% up to $0.301 on no news; however the company is expected to release Q4 results today after the close of the market. . Headquartered in Largo, Florida, GeoPharma researches, develops, manufactures, and brings to market branded generic pharmaceuticals, veterinary products, health products, and functional foods.  The company is registered with both the Food and Drug Administration and the Drug Enforcement Administration.

To be kept up to date on all of our hot stock information join us at Picks That Move.

About PicksThatMove.com:

PicksThatMove.com is an independent electronic publication that provides information on selected publicly traded companies.  PicksThatMove.com is not a registered investment advisor or broker-dealer.  PicksThatMove.com affiliates, officers, directors and employees may buy and sell shares in any company mentioned herein and may profit in the event those shares rise in value.  We recommend Due Diligence before investing in any stock. 

Subscribe NOW to our newsletters by clicking on the following link: http://picksthatmove.com/join-now/.   Feel free to visit our communities on Facebook and Twitter

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) rose 16.00% up to $7.25, on no news since the company reported stellar 2009 Q4 and end of year financial results last week.  Highlights of the report include an increase in net income for the last quarter of 2009 up to $15.2 million, or $0.37 per basic share, compared to net income of $10.1 million, or $0.26 per share for the same quarter of 2008. Total revenues also grew to $74.6 million for the year ended December 31, 2009, up from $56.6 million for the year ended December 31, 2008.  Based in Birmingham, Alabama, BioCryst Pharmaceuticals develops small-molecule drugs for treatment of immunological, viral, and cardiovascular diseases and disorders.  The company’s lead flu drug Peravimir has already begun selling Japan under the name Rapiacta. The US government has approved BioCryst’s Peramivir for the emergency treatment for swine flu. The company expects to continue testing Peramivir until 2011 to win full FDA approval in the U.S. BCRX has gained 494% from a 52 week trading low $1.16 in March.

A.P. Pharma, Inc. (NASDAQ:APPA) gained 15.12% up to $1.90 on no news. In January the company received a milestone royalty payment of $2.5 million for rights to Retin-A Micro and Carac it sold to an affiliate of Paul Capital Healthcare. Based in Redwood City, California, A.P. Pharma, Inc., is a pharmaceutical company developing pharmaceutical products applying its proprietary Biochronomer polymer-based drug delivery technology. Its lead product candidate is APF530, which completed pivotal Phase III clinical trial for the prevention of chemotherapy-induced nausea and vomiting. The New Drug Application (NDA) for APF530 was submitted to the FDA in May 2009 and accepted for review in July 2009, at which time the FDA set a Prescription Drug User Fee Act (PDUFA) date of March 18, 2010.

 To be kept up to date on all of our hot stock information join us at Picks That Move.

About PicksThatMove.com:

PicksThatMove.com is an independent electronic publication that provides information on selected publicly traded companies.  PicksThatMove.com is not a registered investment advisor or broker-dealer.  PicksThatMove.com affiliates, officers, directors and employees may buy and sell shares in any company mentioned herein and may profit in the event those shares rise in value.  We recommend Due Diligence before investing in any stock. 

Subscribe NOW to our newsletters by clicking on the following link: http://picksthatmove.com/join-now/.   Feel free to visit our communities on Facebook and Twitter

ConjuChem Biotechnologies Inc. (TSE:CJB) gained 15.00% up to $0.115 on no news since the end of January when the company announced its fiscal 2009 year end results. Based in Montreal, Quebec, ConjuChem Biotechnologies is biotechnology firm dedicated to the discovery of therapeutics focused on curing diabetes, cancer and HIV. The biotech firm currently has three drug candidates in development and the company’s diabetes treatment PC-DAC Exendin-4 recently achieved promising glycemic control and weight loss in Phase II clinical trials for Type 2 diabetes.

Ligand Pharmaceuticals Inc. (NASDAQ:LGND) rose 6.37% up to $1.67 on news the company reported financial results for the quarter and 12 month period ended December 31, 2009.  The biotech company posted profits of $3 million, or +3 cents per share, up from a loss of $69.6 million, or - 72 cents per share in 2008, a loss due chiefly to cost absorbed as part of $72 million purchase of the biotechnology company Pharmacopeia.  Revenue grew 13% to $14 million compared to $12.4 million for the same period in 2008.  Ligand also provided guidance for 2010 and updates on key programs. Based in San Diego, California, Ligand discovers and develops new drugs for unmet medical needs including hepatitis, muscle wasting, frailty, inflammation, anaemia, asthma, rheumatoid arthritis and osteoporosis. Ligand has strategic partnerships with big pharmaceutical and biotechnology companies, including GlaxoSmithKline, Merck, Pfizer, Roche, Celgene, and Cephalon etc.

Naturewell, Inc. (OTC:NAWL) jumped 50.00% up to $0.0003 on no news. Based in San Diego, California, Naturewell researches and develops proprietary healthcare products for various conditions, including its migraine medication, Migraspray. NAWL has gained 200% since October 2009.

Trubion Pharmaceuticals, Inc. (NASDAQ:TRBN) advanced 23.81% up to $3.90 on no news. Based in Seattle, Washington, Trubion is a biopharmaceutical company creating a pipeline of novel protein therapeutic product candidates to treat autoimmune and inflammatory diseases and cancer.

 To be kept up to date on all of our hot stock information join us at Picks That Move.

About PicksThatMove.com:

PicksThatMove.com is an independent electronic publication that provides information on selected publicly traded companies.  PicksThatMove.com is not a registered investment advisor or broker-dealer.  PicksThatMove.com affiliates, officers, directors and employees may buy and sell shares in any company mentioned herein and may profit in the event those shares rise in value.  We recommend Due Diligence before investing in any stock. 

Subscribe NOW to our newsletters by clicking on the following link: http://picksthatmove.com/join-now/.   Feel free to visit our communities on Facebook and Twitter

RCM Technologies, Inc. (NASDAQ:RCMT) gained 12.00% to close at $2.80 and picked up from a low today of $2.86, on news the company’s Board of Directors have implemented a stock repurchase program for up to $7.5 million of RCTM’s outstanding common shares over the next 12 months. The stock repurchase program will be funded using the company’s working capital. Headquartered in Pennsauken, New Jersey, RCM Technologies, Inc. is an international technology company providing engineering services and IT division consulting.  RCTM’s stock is bullish and trading well above its 90 day moving average of $2.49 and has gained 210% from a 52 week trading low in March when the stock was moving at around $0.91.

Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC) up 16.16% to close at $2.30 on no news; however the company will be participating at the upcoming 12th Annual BIO CEO & Investor Conference on Monday the 8^th of February, and will provide an overview of key developments. In January the company’s lead drug candidate Seliciclib was reviewed by two medical journals and found be effective in killing lung cancer cells through induction of cancer cell suicide; which sent the stock surging 152%. Headquartered in Berkeley Heights, New Jersey, Cyclacel Pharmaceuticals, Inc., is a development-stage biopharmaceutical company which discovers, develops, and commercializes novel, mechanism-targeted drugs to treat human cancers and other serious illnesses.  The company currently has 3 drug candidates in 7 clinical trial studies for the treatment of various cancers. 

 To be kept up to date on all of our hot stock information join us at Picks That Move.

About PicksThatMove.com:

PicksThatMove.com is an independent electronic publication that provides information on selected publicly traded companies.  PicksThatMove.com is not a registered investment advisor or broker-dealer.  PicksThatMove.com affiliates, officers, directors and employees may buy and sell shares in any company mentioned herein and may profit in the event those shares rise in value.  We recommend Due Diligence before investing in any stock. 

Subscribe NOW to our newsletters by clicking on the following link: http://picksthatmove.com/join-now/.   Feel free to visit our communities on Facebook and Twitter

Encorium Group Inc. (NASDAQ:ENCO) bounced 21.15% to close at $0.315 surging on heavy volume on no news.  Headquartered in Wayne, Pennsylvania, Encorium designs and manages clinical trials for lead pharmaceutical, biotechnology, and medical device industries primarily in the US and Europe.   Encorium Group stock is trading above its 200 day moving average of $0.29.

EntreMed, Inc. (NASDAQ:ENMD) gained 15.35% to close at $0.750 on no official news since the company received notice that its common stock will face delisting from the Nasdaq because it has failed to sustain a minimum bid of $1.00.  EntreMed requested a court hearing on the matter and was able to extend trading, which without a hearing request, the stock would have been delisted today, the 28^th of January. Headquartered in Rockville, Maryland, EntreMed is a clinical-stage pharmaceutical company which develops drug candidates chiefly for the treatment of cancer and inflammation.  The company has four drug candidates in clinical trials, including ENMD-2076, MKC-1, ENMD-1198, Panzem for the treatment of various advanced cancers.

Oncolytics Biotech, Inc. (USA) (NASDAQ:ONCY) rose 14.29% up to $2.40 on no news. On Monday the company participated at the 8th Annual BioPartnering North America (BPN) Conference, in Vancouver, British Columbia.  Headquartered in Calgary, Alberta, Oncolytics Biotech, Inc is a biopharmaceutical company which discovers and develops therapeutic products for the treatment of cancer.  The company currently has more than a dozen trials at various stages in the US, UK and Canada for their lead drug candidate Reolysin, for the treatment of neck cancer. The company has a market cap of about $136 million and the financial wherewithal to market the drug pending FDA approval.

To be kept up to date on all of our hot stock information join us at Picks That Move.

About PicksThatMove.com:

PicksThatMove.com is an independent electronic publication that provides information on selected publicly traded companies.  PicksThatMove.com is not a registered investment advisor or broker-dealer.  PicksThatMove.com affiliates, officers, directors and employees may buy and sell shares in any company mentioned herein and may profit in the event those shares rise in value.  We recommend Due Diligence before investing in any stock. 

Subscribe NOW to our newsletters by clicking on the following link: http://picksthatmove.com/join-now/.   Feel free to visit our communities on Facebook and Twitter

La Jolla Pharmaceutical Company (NASDAQ:LJPC) advanced 23.36% up to $0.1360 on no news; however the biopharmaceutical company announced this week it expects that NASDAQ will take action to begin proceedings to delist the company’s common stock. Based in San Diego, California La Jolla Pharmaceutical Company is a biopharmaceutical company focused on the discovery and development of small molecule therapy for the treatment of autoimmune diseases, and acute and chronic inflammatory disorders and acute and chronic inflammatory disorders such as Lupus.

CombinatoRx, Incorporated (NASDAQ:CRXX) rose 14.02% up to $1.22 on no news since the company announced changes to its senior management team following its merger with Neuromed.  The company expects news on February 22nd from the FDA regarding a review of the New Drug Application for Neuromed’s drug candidate Exalgo for pain management.  CRXX is surging on heavy volume and trading above its 200 day moving average of $1.05.  Based in Cambridge, Massachusetts, CombinatoRx, Inc., is a biopharmaceutical company which discovers, develops, and out-licenses combination pharmaceuticals created by blending drugs to treat various diseases, cancer, metabolic diseases, inherited diseases, and other medical conditions.

 To be kept up to date on all of our hot stock information join us at Picks That Move.

About PicksThatMove.com:

PicksThatMove.com is an independent electronic publication that provides information on selected publicly traded companies.  PicksThatMove.com is not a registered investment advisor or broker-dealer.  PicksThatMove.com affiliates, officers, directors and employees may buy and sell shares in any company mentioned herein and may profit in the event those shares rise in value.  We recommend Due Diligence before investing in any stock. 

Subscribe NOW to our newsletters by clicking on the following link: http://picksthatmove.com/join-now/.   Feel free to visit our communities on Facebook and Twitter

GeoPharma, Inc. (NASDAQ:GORX) gained 28.38% up to $0.501, on no news but surging on heavy volume. Headquartered in Largo, Florida, GeoPharma researches, develops, manufactures, and brings to market branded generic pharmaceuticals, veterinary products, health products, and functional foods.  The company is registered with both the Food and Drug Administration and the Drug Enforcement Administration.

GenVec, Inc. (NASDAQ:GNVC) jumped 32.64% up to $3.17 with 8,374,308 shares actively trading this afternoon, on news the company revealed remarkable long term survival analysis in patients with advanced oesophageal cancer.  GenVec presented the conclusive data at the American Society of Clinical Oncology’s 2010 Gastrointestinal Cancer Symposium in Orlando today. The innovative procedure applies endoscopy and endoscopic ultrasound  guided fine needle injection of their proprietary antitumor agent, the result was a median survival of 47.7 months; compared to historical clinical trials in similar stage disease with median survival rates of only 9.7 to 34 months. Gaithersburg, Maryland, GenVec, Inc., GenVec, Inc. a clinical stage biopharmaceutical company developing gene-based therapeutic drugs and vaccines in the US. The company’s pipeline includes TNFerade biologic, currently under Phase III trial for first-line treatment of inoperable, locally advanced pancreatic cancer; and TNFerade biologic, for the treatment of various cancers, including oesophageal cancer, rectal cancer, and head and neck cancer.

 To be kept up to date on all of our hot stock information join us at Picks That Move.

About PicksThatMove.com:

PicksThatMove.com is an independent electronic publication that provides information on selected publicly traded companies.  PicksThatMove.com is not a registered investment advisor or broker-dealer.  PicksThatMove.com affiliates, officers, directors and employees may buy and sell shares in any company mentioned herein and may profit in the event those shares rise in value.  We recommend Due Diligence before investing in any stock. 

Subscribe NOW to our newsletters by clicking on the following link: http://picksthatmove.com/join-now/.   Feel free to visit our communities on Facebook and Twitter

IsoRay, Inc. (AMEX:ISR) skyrocketed 110.98% up to $1.730 at midday on news the company announced positive results from the world’s first Cesium-131(Cs-131) implant for the treatment of colorectal cancer which was performed in October 2009 at the Weill Cornell Medical Center in New York. The patient tolerated the implant procedure well, and has had no adverse effects attributed to the use of IsoRay’s proprietary Cs-131 seeds, and no indications the cancer reoccurred.  In September IsoRay reported similar positive results for tests of the world’s first Cesium-131 implant for recurrent head and neck cancer. Headquartered in Richland, Washington, IsoRay, Inc. develops, manufactures, and commercializes isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the US and internationally.  IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc., is the only producer of the Cesium-131 brachytherapy seed.  ISR stock has appreciated 635% since July.

To be kept up to date on all of our hot stock information join us at Picks That Move.

About PicksThatMove.com:

PicksThatMove.com is an independent electronic publication that provides information on selected publicly traded companies.  PicksThatMove.com is not a registered investment advisor or broker-dealer.  PicksThatMove.com affiliates, officers, directors and employees may buy and sell shares in any company mentioned herein and may profit in the event those shares rise in value.  We recommend Due Diligence before investing in any stock. 

Subscribe NOW to our newsletters by clicking on the following link: http://picksthatmove.com/join-now/.   Feel free to visit our communities on Facebook and Twitter

Antigenics, Inc. (NASDAQ:AGEN) rose 40.40% up to $1.09 with 7,445,439 shares moving on no news in early afternoon trading.  Headquartered in Lexington, Massachusetts the biotechnology company develops cancer vaccines and other treatments for cancer and infectious diseases.

Pharmacyclics, Inc. (NASDAQ:PCYC) gained 19.66% up to $4.20, to a 52 week high on no news; and up 635% since last February when the stock was trading at a low of $0.57. Headquartered in Sunnyvale, California, Pharmacyclics, Inc. is a clinical-stage biopharmaceutical company which develops and commercializes small-molecule drugs for the treatment of auto-immune diseases and cancer. The company’s products in clinical development include HDAC Inhibitor for advanced solid tumours, recurrent lymphomas, and sarcoma; Btk Inhibitors for the treatment of lymphoma and auto-immune diseases; Factor VIIa Inhibitor for pancreatic cancer; and Motexafin Gadolinium for brain cancer.

To be kept up to date on all of our hot stock information join us at Picks That Move.

About PicksThatMove.com:

PicksThatMove.com is an independent electronic publication that provides information on selected publicly traded companies.  PicksThatMove.com is not a registered investment advisor or broker-dealer.  PicksThatMove.com affiliates, officers, directors and employees may buy and sell shares in any company mentioned herein and may profit in the event those shares rise in value.  We recommend Due Diligence before investing in any stock. 

Subscribe NOW to our newsletters by clicking on the following link: http://picksthatmove.com/join-now/.   Feel free to visit our communities on Facebook and Twitter

MDRNA, Inc. (NASDAQ:MRNA) jumped 54.89% up to $1.47 with 18,036,294 shares trading this morning on news the company ‘s proprietary UsiRNA technology drastically reduced tumour growth in living models with liver and bladder cancer. This is the second study which has been established with a major international pharmaceutical company, and both in vivo trials revealed the efficacy and potency of the anti cancer treatment to shrink carcinogenic lesions.  The company says it’s on track to meet mid 2010 goals to the complete rigorous R&D schedule for their therapeutic candidate. Headquartered in Bothell, Washington, MDRNA, Inc is a biotechnology company which develops and commercializes therapeutic products based on RNA interference.  RNA molecules are linked together like DNA chains which are found in all living organisms and viruses.  RNA’s contribute to protein synthesis and the transmission of genetic information.  MDRNA stock has appreciated 450% since last March.

Rosetta Genomics Ltd. (USA) (NASDAQ:ROSG) surged 77.30% up to $3.28 on news  the results of a study by Johns Hopkins University researchers was published and demonstrated miRview  squamous accurately identified  non small cell lung cancer, with a much higher rate of precision than biopsies.  The impact of this discovery will help physicians make crucial lung cancer classification and diagnosis.  Based in Rehovot, Israel, Rosetta Genomics Ltd. develops microRNA-based diagnostic and therapeutic products in Israel. Rosetta Genomics develops diagnostic programs for various cancers, as well as for the identification of the origin of the primary tumour of metastases; for differentiating squamous from non squamous non-small cell lung cancer; and for differentiating mesothelioma from other tumours in the lungs and chest.

To be kept up to date on all of our hot stock information join us at Picks That Move.

About PicksThatMove.com:

PicksThatMove.com is an independent electronic publication that provides information on selected publicly traded companies.  PicksThatMove.com is not a registered investment advisor or broker-dealer.  PicksThatMove.com affiliates, officers, directors and employees may buy and sell shares in any company mentioned herein and may profit in the event those shares rise in value.  We recommend Due Diligence before investing in any stock. 

Subscribe NOW to our newsletters by clicking on the following link: http://picksthatmove.com/join-now/.   Feel free to visit our communities on Facebook and Twitter